跳至主要内容
临床试验/NCT01047202
NCT01047202已完成4 期

A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants

Sinovac Biotech Co., Ltd1 个研究点 分布在 1 个国家目标入组 310 人开始时间: 2009年12月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
310
试验地点
1
主要终点
Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in infants

研究概览

简要总结

A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU.1).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
6 Months 至 35 Months(Child)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy male or female aged between 6 and 35 months
  • •Full-term birth, birth weight 2,500 grams or more
  • •provided birth certification or vaccination card Parent(s) or legal guardian(s) are able to understand and sign the informed consent

排除标准

  • •Cases, cured cases and close contact of influenza A (H1N1) virus
  • •Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
  • •Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  • •Symptoms of acute infection within a week
  • •Autoimmune disease or immunodeficiency
  • •Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)
  • •Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
  • •Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  • •History or family history of convulsions, epilepsy, brain disease and psychiatric
  • •Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
  • •Guillain-Barre Syndrome
  • •Administration of 2009-2010 seasonal vaccine
  • •History of any blood products within 3 months
  • •Administration of any other investigational research agents within 30 days
  • •Administration of any live attenuated vaccine within 30 days
  • •Administration of subunit or inactivated vaccines within 14 days
  • •Be receiving anti-TB prophylaxis or therapy currently
  • •Axillary temperature > 37.0 centigrade at the time of dosing
  • •Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

研究组 & 干预措施

Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine

Experimental

120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart

干预措施: Pandemic influenza A/H1N1 vaccine (Biological)

Group 2 : 15 μg pandemic influenza A/H1N1 vaccine

Experimental

120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart

干预措施: Pandemic influenza A/H1N1 vaccine (Biological)

Group 3 : 7.5 μg seasonal trivalent vaccine

Sham Comparator

60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart

干预措施: Seasonal trivalent vaccine (Biological)

结局指标

主要结局

Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in infants

时间窗: 3 months

次要结局

  • Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in infants(3 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验